ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pregabalin

Also written as “pregabalin”, “pregabalin (Lyrica)” and “Pregabalin ER”.

Its studies are mostly in Neuralgia · Fibromyalgia · Diabetic Neuropathies · Epilepsies, Partial · Neuralgia, Postherpetic, led by 18 companies.

Drug pagePregabalin: every studyMany companies study it; this page follows only the 142 they lead. All 390 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 31, 2005142 company-led studies, 1 open or runningNext primary completion: Jun 1, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatrisits history only940 open or runningphase 4since Aug 31, 2005Aug 30, 2005none ahead
Pfizer180 open or runningphase 4since Apr 16, 2012Aug 30, 2005none ahead
Yuhanits history only80 open or runningphase 4since Apr 13, 2021Aug 17, 2011none ahead
GL Pharm Techits history only40 open or runningphase 1since Jul 4, 2012Jul 4, 2012none ahead
Laboratorios Silanes S.A. de C.V.its history only30 open or runningphase 3since Apr 4, 2022Apr 4, 2022none ahead
Merckits history only20 open or runningphase 1since Dec 7, 2007Dec 7, 2007none ahead
Nevakarits history only20 open or runningphase 2since Jul 27, 2020Jan 29, 2020none ahead
Analgesic Solutionsits history only10 open or runningphase 4since Dec 13, 2012Dec 13, 2012none ahead
Depomedits history only10 open or runningphase 4since Jun 5, 2017Jun 5, 2017none ahead
Dexa Medica Groupits history only10 open or runningno phasesince Sep 4, 2014Sep 4, 2014none ahead

Also a collaborator on its studies: Nevakar Injectables, Boehringer Ingelheim and Astellas Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 30, 2005First studies: 7 phase 3 studiesFirst studyNCT00143143, NCT00141401, NCT00141388 and 4 more
  2. Aug 30, 2005Phase 2 study in Epilepsies, PartialNCT00141414 · 82 enrolled · United States, Germany
  3. Sep 6, 20054 phase 3 studiesNCT00150449, NCT00150436, NCT00150423 and 1 more
  4. Jun 7, 2006Phase 2 study in PainNCT00334685 · 136 enrolled · United States, Austria, Canada and more
  5. Mar 19, 2008Phase 3 study in Sleep DeprivationNCT00643136 · 17 enrolled · Netherlands
  6. Apr 2, 2008Phase 2 study in Urinary Bladder, OveractiveNCT00746681 · 188 enrolled · Czech Republic, Lithuania, Norway and more
  7. May 4, 2010No phase study in NeuralgiaNCT01117766 · 31 enrolled · Austria, Belgium, France and more
  8. Apr 16, 2012Phase 4 study in Neuralgia, PostherpeticNCT01603394 · 9 enrolled · United States, Austria, Germany and more
  9. Aug 11, 2014Phase 2 study in Diabetic NeuropathiesNCT02215252 · 141 enrolled · United States
  10. Jun 9, 2019Named pregabalinINNProposed as its International Nonproprietary Name in WHO's List 121

TargetBeta

“Voltage-gated calcium channel modulator”ChEMBL 37, by rule

Other programs on the same 26 targets

ProgramCompanyFurthest phaseStudies
GabapentinruleViatrisphase 449

Studies

All 18 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02215252Diabetic Neuropathies · United States2CompletedJul 15, 2015141
NCT01603394Neuralgia, Postherpetic · United States, Austria, Germany and more4TerminatedJun 20139
NCT01117766Neuralgia · Austria, Belgium, France and more–CompletedSep 200931
NCT00746681Urinary Bladder, Overactive · Czech Republic, Lithuania, Norway and more2Completed188
NCT00643136Sleep Deprivation · Netherlands3Completed17
NCT00334685Pain · United States, Austria, Canada and more2TerminatedOct 4, 2007136
NCT00150449Anxiety Disorders · Austria, Belgium, Estonia and more3Completed511
NCT00150436Neuralgia3Completed276
NCT00150423Diabetic Neuropathies3Completed384
NCT00150293Epilepsies, Partial · Australia, Austria, Belgium and more3Completed337
NCT00143143Epilepsies, Partial · Austria, Canada, France and more3Completed300
NCT00141414Epilepsies, Partial · United States, Germany2Completed82
NCT00141401Diabetic Neuropathies3Completed240
NCT00141388Epilepsies, Partial · United States, Canada3Completed455
NCT00141375Neuralgia · Australia3Completed132
NCT00141362Pain3Completed325
NCT00141336Epilepsies, Partial · United States, Canada3Completed750
NCT00141245Epilepsies, Partial · Australia, Austria, Belgium and more3Completed325

How it is read

Names in the registry

  • “Pregabalin”, 80 entries
  • “pregabalin”, 43 entries
  • “pregabalin (Lyrica)”, 7 entries
  • “Pregabalin ER”, 6 entries
  • “Pregabalin 150mg”, 5 entries

Codes read as this program: YHD1119.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.